

Jeffrey C Fink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5087447/publications.pdf>

Version: 2024-02-01

138
papers

8,422
citations

61984

43
h-index

48315

88
g-index

140
all docs

140
docs citations

140
times ranked

9036
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1685-1693.	0.7	14
2	Progression of retinopathy and incidence of cardiovascular disease: findings from the Chronic Renal Insufficiency Cohort Study. <i>British Journal of Ophthalmology</i> , 2021, 105, 246-252.	3.9	9
3	Subtyping CKD Patients by Consensus Clustering: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 639-653.	6.1	41
4	Associations of Performance-Based Functional Assessments and Adverse Outcomes in CKD. <i>Kidney360</i> , 2021, 2, 629-638.	2.1	3
5	Adiposity, Physical Function, and Their Associations With Insulin Resistance, Inflammation, and Adipokines in CKD. <i>American Journal of Kidney Diseases</i> , 2021, 77, 44-55.	1.9	22
6	Digital Solutions to Improve Medication Safety in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 499-501.	4.5	0
7	Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2021, 78, 837-845.e1.	1.9	15
8	Mobile Health (mHealth) Technology: Assessment of Availability, Acceptability, and Use in CKD. <i>American Journal of Kidney Diseases</i> , 2021, 77, 941-950.e1.	1.9	49
9	Quantifying human performance for heterogeneous user populations using a structured expert elicitation. <i>Safety Science</i> , 2021, 143, 105435.	4.9	4
10	Device personalization for heterogeneous populations: leveraging physician expertise and national population data to identify medical device patient user groups. <i>User Modeling and User-Adapted Interaction</i> , 2021, 31, 979-1025.	3.8	3
11	Continuous Glucose Monitoring in General Wards for Prevention of Hypoglycemia: Results From the Glucose Telemetry System Pilot Study. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 783-790.	2.2	19
12	Association of glucose variability at the last day of hospitalization with 30-day readmission in adults with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000990.	2.8	6
13	Inflammatory Markers and Incidence of Hospitalization With Infection in Chronic Kidney Disease. <i>American Journal of Epidemiology</i> , 2020, 189, 433-444.	3.4	11
14	Fibroblast Growth Factor 23 and Risk of Hospitalization with Infection in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1836-1846.	6.1	17
15	Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 184-193.	1.9	35
16	In Reply to "No Obvious Impact of NSAIDs on Risk of Kidney Failure: Causal or Another Selection Bias"™. <i>American Journal of Kidney Diseases</i> , 2020, 76, 742-743.	1.9	1
17	Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003470.	8.4	33
18	Development and usability testing of a patient safety educational tool in chronic kidney disease (Preprint). <i>JMIR Formative Research</i> , 2020, 4, e16137.	1.4	5

#	ARTICLE	IF	CITATIONS
19	Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. , 2020, 17, e1003470.		0
20	Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. , 2020, 17, e1003470.		0
21	Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. , 2020, 17, e1003470.		0
22	Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. , 2020, 17, e1003470.		0
23	Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. , 2020, 17, e1003470.		0
24	Hospitalizations among adults with chronic kidney disease in the United States: A cohort study. , 2020, 17, e1003470.		0
25	Text preprocessing for improving hypoglycemia detection from clinical notes â€“ A case study of patients with diabetes. International Journal of Medical Informatics, 2019, 129, 374-380.	3.3	13
26	Association of Glucose Concentrations at Hospital Discharge With Readmissions and Mortality: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3679-3691.	3.6	22
27	Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatographyâ€“Inductively Coupled Plasmaâ€“Mass Spectrometric Approach. Molecular Pharmaceutics, 2019, 16, 1272-1281.	4.6	14
28	Association Between Progression of Retinopathy and Concurrent Progression of Kidney Disease. JAMA Ophthalmology, 2019, 137, 767.	2.5	28
29	Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. Nephrology Dialysis Transplantation, 2019, 34, 1145-1154.	0.7	35
30	Usability Testing of a Sick-Day Protocol in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 583-585.	4.5	15
31	Use of a Medical-Alert Accessory in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 994-1001.	4.5	1
32	Health Behaviors in Younger and Older Adults With CKD: Results From the CRIC Study. Kidney International Reports, 2019, 4, 80-93.	0.8	17
33	The Effect of Continuous Glucose Monitoring in Preventing Inpatient Hypoglycemia in General Wards: The Glucose Telemetry System. Journal of Diabetes Science and Technology, 2018, 12, 20-25.	2.2	50
34	Disease Specific Ontology of Adverse Events: Ontology extension and adaptation for Chronic Kidney Disease. Computers in Biology and Medicine, 2018, 101, 210-217.	7.0	10
35	Self-Reported Tobacco, Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 993-1001.	4.5	50
36	Medication Safety Principles and Practice in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1738-1746.	4.5	66

#	ARTICLE	IF	CITATIONS
37	Ensuring Patient Safety During the Transition to ESRD. <i>Seminars in Nephrology</i> , 2017, 37, 194-208.	1.6	4
38	Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (<scp>MAGMA</scp>) Trial. <i>Clinical Cardiology</i> , 2017, 40, 633-640.	1.8	8
39	A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , 2017, 46, 364-370.	3.1	7
40	Deprescribing in CKD: The Proof Is in the Process. <i>American Journal of Kidney Diseases</i> , 2017, 70, 596-598.	1.9	12
41	Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1409-1417.	4.5	18
42	Are Ambulatory Care Sensitive Conditions the Fulcrum of Hospitalizations for CKD Patients?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1927-1928.	4.5	0
43	Influence of Nephrologist Care on Management and Outcomes in Adults with Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2016, 31, 22-29.	2.6	38
44	Patient-Reported Safety Events in Chronic Kidney Disease Recorded With an Interactive Voice-Inquiry Dial-Response System: Monthly Report Analysis. <i>Journal of Medical Internet Research</i> , 2016, 18, e125.	4.3	8
45	The Effect of Contact Precautions on Frequency of Hospital Adverse Events. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 1268-1274.	1.8	31
46	Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 654-662.	1.9	5
47	The Effect of Universal Glove and Gown Use on Adverse Events in Intensive Care Unit Patients. <i>Clinical Infectious Diseases</i> , 2015, 61, 545-553.	5.8	18
48	Chronic Pain and Analgesic Use in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 435-442.	4.5	43
49	Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1364-1370.	4.5	31
50	Self-reported Medication Adherence and Adverse Patient Safety Events in CKD. <i>American Journal of Kidney Diseases</i> , 2015, 66, 621-629.	1.9	44
51	Patient Safety Issues in CKD: Core Curriculum 2015. <i>American Journal of Kidney Diseases</i> , 2015, 66, 159-169.	1.9	21
52	Retinopathy and the Risk of Cardiovascular Disease in Patients With Chronic Kidney Disease (from the) <i>TJ ETQq0 0 0 rgBT /Overlock 10 T</i>	1.6	15
53	Chronic Renal Insufficiency Cohort Study (CRIC). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2073-2083.	4.5	87
54	Healthy Lifestyle and Risk of Kidney Disease Progression, Atherosclerotic Events, and Death in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 412-424.	1.9	150

#	ARTICLE	IF	CITATIONS
55	Association between Inflammation and Cardiac Geometry in Chronic Kidney Disease: Findings from the CRIC Study. PLoS ONE, 2015, 10, e0124772.	2.5	59
56	Patient-Reported and Actionable Safety Events in CKD. Journal of the American Society of Nephrology: JASN, 2014, 25, 1564-1573.	6.1	30
57	Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. Current Opinion in Nephrology and Hypertension, 2014, 23, 306-313.	2.0	39
58	Association of Kidney Disease Outcomes With Risk Factors for CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2014, 63, 236-243.	1.9	100
59	Differences in Health Services Utilization and Costs between Antihypertensive Medication Users Versus Nonusers in Adults with Diabetes and Concomitant Hypertension from Medical Expenditure Panel Survey Pooled Years 2006 to 2009. Value in Health, 2014, 17, 51-61.	0.3	5
60	Retinopathy and Progression of CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1217-1224.	4.5	25
61	Usability Testing and Acceptance of an Electronic Medication Inquiry System for CKD Patients. American Journal of Kidney Diseases, 2013, 61, 644-646.	1.9	22
62	Red blood cell transfusion use in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 1504-1515.	0.7	34
63	Telenephrology: a novel approach to improve coordinated and collaborative care for chronic kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 972-981.	0.7	31
64	Consideration of ICD-9 Code-Derived Disease-Specific Safety Indicators in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 2123-2131.	4.5	5
65	APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2183-2196.	27.0	654
66	Directed Use of the Internet for Health Information by Patients With Chronic Kidney Disease: Prospective Cohort Study. Journal of Medical Internet Research, 2013, 15, e251.	4.3	37
67	Finding a Common Language for Patient Safety in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 689-695.	4.5	6
68	Retinopathy and Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort (CRIC) Study. JAMA Ophthalmology, 2012, 130, 1136.	2.4	117
69	Usability of a CKD Educational Website Targeted to Patients and Their Family Members. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1553-1560.	4.5	28
70	Genotype-based changes in serum uric acid affect blood pressure. Kidney International, 2012, 81, 502-507.	5.2	75
71	Critical and Honest Conversations. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1664-1672.	4.5	157
72	Serum Fibroblast Growth Factor-23 and Risk of Incident Chronic Kidney Disease in Older Community-Dwelling Women. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 85-91.	4.5	34

#	ARTICLE	IF	CITATIONS
73	Urinary Sodium Is a Potent Correlate of Proteinuria: Lessons from the Chronic Renal Insufficiency Cohort Study. <i>American Journal of Nephrology</i> , 2012, 36, 397-404.	3.1	12
74	Vascular access hemorrhages contribute to deaths among hemodialysis patients. <i>Kidney International</i> , 2012, 82, 686-692.	5.2	63
75	Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal Anti-Inflammatory Drug Prescriptions in Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2012, 36, 19-26.	3.1	18
76	Association Between Retinopathy and Cardiovascular Disease in Patients With Chronic Kidney Disease (from the Chronic Renal Insufficiency Cohort [CRIC] Study). <i>American Journal of Cardiology</i> , 2012, 110, 246-253.	1.6	45
77	A Varying Patient Safety Profile Between Black and Nonblack Adults With Decreased Estimated GFR. <i>American Journal of Kidney Diseases</i> , 2012, 60, 47-53.	1.9	12
78	Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. <i>Kidney International</i> , 2011, 80, 288-294.	5.2	57
79	Longitudinal Association of Depressive Symptoms with Rapid Kidney Function Decline and Adverse Clinical Renal Disease Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 834-844.	4.5	70
80	Endogenous Secretory Receptor for Advanced Glycation End Products and Chronic Kidney Disease in the Elderly Population. <i>American Journal of Nephrology</i> , 2011, 33, 313-318.	3.1	10
81	Metabolic Syndrome, Components, and Cardiovascular Disease Prevalence in Chronic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Nephrology</i> , 2011, 33, 477-484.	3.1	29
82	Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2403-2410.	4.5	37
83	The effect of CKD therapies on serum potassium levels. <i>Nature Reviews Nephrology</i> , 2010, 6, 633-634.	9.6	4
84	Adverse Safety Events in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 95-101.	4.5	47
85	Prevalence of Ocular Fundus Pathology in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 867-873.	4.5	65
86	Pre-Clinical Myocardial Metabolic Alterations in Chronic Kidney Disease. <i>Cardiology</i> , 2010, 116, 160-167.	1.4	14
87	Timing of Erythropoiesis-Stimulating Agent Initiation and Adverse Outcomes in Nondialysis CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 882-888.	4.5	19
88	Serum Carboxymethyl-Lysine, a Dominant Advanced Glycation End Product, Is Associated With Chronic Kidney Disease: The Baltimore Longitudinal Study of Aging. , 2010, 20, 74-81.		48
89	Chronic Kidney Disease as a Potent Risk Modifier for CAD in Diabetics. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 746-748.	5.3	0
90	The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease. <i>Archives of Internal Medicine</i> , 2009, 169, 1156.	3.8	501

#	ARTICLE	IF	CITATIONS
91	Chronic Renal Insufficiency Cohort (CRIC) Study. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1302-1311.	4.5	497
92	Advanced Glycation End Products and Their Circulating Receptors and Level of Kidney Function in Older Community-Dwelling Women. American Journal of Kidney Diseases, 2009, 53, 51-58.	1.9	62
93	CKD as an Underrecognized Threat to Patient Safety. American Journal of Kidney Diseases, 2009, 53, 681-688.	1.9	54
94	Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. European Journal of Nutrition, 2009, 48, 38-44.	3.9	37
95	Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1121-1127.	4.5	339
96	Medication errors in chronic kidney disease: one piece in the patient safety puzzle. Kidney International, 2009, 76, 1123-1125.	5.2	28
97	Do You Need to Stay in School to Get a Kidney Transplant?. American Journal of Kidney Diseases, 2008, 51, 717-718.	1.9	3
98	Deleterious Effect of Altered Myocardial Fatty Acid Metabolism in Kidney Disease. Žaž Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2008, 51, 146-148.	2.8	17
99	A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1332-1338.	4.5	61
100	Chronic Kidney Disease Adversely Influences Patient Safety. Journal of the American Society of Nephrology: JASN, 2008, 19, 2414-2419.	6.1	71
101	Renal Function and Cardiovascular Response to Mental Stress. American Journal of Nephrology, 2008, 28, 304-310.	3.1	5
102	Urinary cotinine as an objective measure of cigarette smoking in chronic kidney disease. Nephrology Dialysis Transplantation, 2007, 22, 1950-1954.	0.7	16
103	Center Effects in Anemia Management of Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2007, 18, 646-653.	6.1	21
104	Cigarette Smoking and Incident Chronic Kidney Disease: A Systematic Review. American Journal of Nephrology, 2007, 27, 342-351.	3.1	53
105	The Relationship Between Dialysis Performance Measures: Adequacy and Anemia Management. American Journal of Kidney Diseases, 2007, 50, 774-781.	1.9	13
106	Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clinical Transplantation, 2007, 21, 491-497.	1.6	20
107	Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. Journal of Clinical Epidemiology, 2006, 59, 1266-1273.	5.0	55
108	An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. American Journal of Nephrology, 2006, 26, 268-275.	3.1	105

#	ARTICLE	IF	CITATIONS
109	Renal Function, Erythropoietin, and Anemia of Older Persons. Archives of Internal Medicine, 2005, 165, 2222.	3.8	110
110	Salt intake and progression of chronic kidney disease: An overlooked modifiable exposure? A commentary. American Journal of Kidney Diseases, 2005, 45, 176-188.	1.9	79
111	N-Terminal Pro-B-Type Natriuretic Peptide for Predicting Coronary Disease and Left Ventricular Hypertrophy in Asymptomatic CKD Not Requiring Dialysis. American Journal of Kidney Diseases, 2005, 46, 35-44.	1.9	119
112	Does dietary salt increase the risk for progression of kidney disease?. Current Hypertension Reports, 2005, 7, 385-391.	3.5	21
113	Utility of the Chronic Disease Score and Charlson Comorbidity Index as Comorbidity Measures for Use in Epidemiologic Studies of Antibiotic-resistant Organisms. American Journal of Epidemiology, 2005, 161, 483-493.	3.4	166
114	Survival Benefit of Recombinant Human Erythropoietin Administration prior to Onset of End-Stage Renal Disease: Variations across Surrogates for Quality of Care and Time. Nephron Clinical Practice, 2005, 101, c79-c86.	2.3	19
115	Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking. Nephrology Dialysis Transplantation, 2005, 20, 2739-2745.	0.7	8
116	Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. Journal of the American College of Cardiology, 2005, 45, 1051-1060.	2.8	225
117	The Use and Interpretation of Quasi-Experimental Studies in Infectious Diseases. Clinical Infectious Diseases, 2004, 38, 1586-1591.	5.8	258
118	Late Calcineurin Inhibitor Withdrawal as a Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant Function. American Journal of Nephrology, 2004, 24, 379-386.	3.1	57
119	Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation, 2004, 77, 422-425.	1.0	31
120	Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clinical Pharmacology and Therapeutics, 2003, 73, 427-434.	4.7	106
121	The Chronic Renal Insufficiency Cohort (CRIC) Study. Journal of the American Society of Nephrology: JASN, 2003, 14, S148-S153.	6.1	545
122	Measuring the Efficacy of a Quality Improvement Program in Dialysis Adequacy with Changes in Center Effects. Journal of the American Society of Nephrology: JASN, 2002, 13, 2338-2344.	6.1	39
123	Clinical Course of Polyoma Virus Nephropathy in 67 Renal Transplant Patients. Journal of the American Society of Nephrology: JASN, 2002, 13, 2145-2151.	6.1	398
124	Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. American Journal of Kidney Diseases, 2002, 39, 753-761.	1.9	10
125	Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: A pilot case-control study. American Journal of Kidney Diseases, 2002, 39, 1096-1101.	1.9	38
126	Use of Erythropoietin Before the Initiation of Dialysis and Its Impact on Mortality. American Journal of Kidney Diseases, 2001, 37, 348-355.	1.9	143

#	ARTICLE	IF	CITATIONS
127	The Inevitability of Renal Function Loss in Patients with Hypercreatinemia. American Journal of Nephrology, 2001, 21, 386-389.	3.1	3
128	Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney International, 2001, 59, 1567-1573.	5.2	166
129	Morphological Spectrum of Polyoma Virus Disease in Renal Allografts: Diagnostic Accuracy of Urine Cytology. American Journal of Transplantation, 2001, 1, 373-381.	4.7	146
130	The outcome of the urban renal patient: The importance of social factors and center effects. Seminars in Nephrology, 2001, 21, 356-361.	1.6	3
131	Effect of Center- Versus Patient-Specific Factors on Variations in Dialysis Adequacy. Journal of the American Society of Nephrology: JASN, 2001, 12, 164-169.	6.1	23
132	Within-center correlation in dialysis adequacy. The conclusions and opinions expressed and methods used herein are those of the author. They do not necessarily reflect HCFA policy. The authors assume full responsibility for the accuracy and completeness of the ideas presented. Ideas and contributions to the author concerning experience in engaging with issues presented are welcomed.. Journal of Clinical Epidemiology, 2000, 53, 79-85.	5.0	14
133	Hemodialysis adequacy in Network 5: Disparity between states and the role of center effects. American Journal of Kidney Diseases, 1999, 33, 97-104.	1.9	12
134	ISLET CELL DAMAGE ASSOCIATED WITH TACROLIMUS AND CYCLOSPORINE: MORPHOLOGICAL FEATURES IN PANCREAS ALLOGRAFT BIOPSIES AND CLINICAL CORRELATION1. Transplantation, 1999, 68, 396-402.	1.0	298
135	INCREASED INCIDENCE OF POSTOPERATIVE INFECTIONS ASSOCIATED WITH PERITONEAL DIALYSIS IN RENAL TRANSPLANT RECIPIENTS. Transplantation, 1999, 68, 535-540.	1.0	52
136	Increased risk of adverse maternal and infant outcomes among women with renal disease. Paediatric and Perinatal Epidemiology, 1998, 12, 277-287.	1.7	48
137	A NOVEL APPROACH TO THE TREATMENT OF CHRONIC ALLOGRAFT NEPHROPATHY1. Transplantation, 1997, 64, 1706-1710.	1.0	140
138	A decision aid for referring patients with systolic murmurs for echocardiography. Journal of General Internal Medicine, 1994, 9, 479-484.	2.6	31